Note 13 - Equity Transactions

12 Months Ended

Jun. 30, 2014

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Note 13. Equity Transactions

(a) Stock Option Plan. The Company has adopted a stock option plan for the granting of options or restricted shares to employees, officers, directors and consultants of the Company that originally provided for the purchase of up to 7,000,000 shares of common stock, at the discretion of the Board of Directors. Subsequent to the adoption, the Board of Directors and stockholders approved additional common stock shares aggregating 6,000,000 to be available for grant, for a total of 13,000,000 shares of common stock reserved for issuance under the Company’s 2001 Stock Option Plan, as amended. Stock option grants may not be priced less than the fair market value of the Company’s common stock at the date of grant. Options granted are generally for ten-year periods, except that incentive stock options granted to a 10% stockholder (as defined) are limited to five-year terms.

The following options, warrants and potentially dilutive shares for convertible notes payable (see Note 6. Senior Credit Facility, Subordinated Convertible Note Payable, net - CD Financial, LLC and other Long Term Debt) were not included in the computation of weighted average diluted common shares outstanding as the effect of doing so would be anti-dilutive for fiscal years ended June 30, 2014 and 2013:

	Fiscal Year Ended
	June 30,
	2014		2013
Anti-dilutive stock options		1,236,770		2,269,088
Anti-dilutive warrants		-		500,000
Anti-dilutive shares for convertible notes payable		8,230,769		8,230,769
Total anti-dilutive shares		9,467,539		10,999,857

During the fiscal year ended June 30, 2014 and 2013, the Company did not incur any stock compensation expense.

The intrinsic value of options outstanding and exercisable at June 30, 2014 and 2013 was $68 and $74, respectively.

A summary of the Company’s stock option activity, and related information for the years ended June 30, follows:

				Weighted
				Average
				Exercise
	Options			Price
Outstanding as of July 1, 2012		2,915,338		$	5.54
Granted		-			-
Exercised		-			-
Terminated		(24,000	)		0.75
Expired		(92,500	)		1.47
Outstanding as of June 30, 2013		2,798,838			5.72
Granted		-			-
Exercised		(25,000	)		0.14
Terminated		(73,000	)		2.31
Expired		(976,318	)		9.04
Outstanding as of June 30, 2014		1,724,520		$	4.07
Exercisable at June 30, 2013		2,798,838		$	5.72
Exercisable at June 30, 2014		1,724,520		$	4.07

The following table summarizes the range of exercise prices and weighted-average exercise prices for stock options outstanding and exercisable as of June 30, 2014 under the Company’s stock option plans:

									Weighted
									Average
							Weighted		Remaining				Weighted
Range of							Average		Contractual				Average
Exercise Price					Outstanding		Exercise Price		Life (years)		Exercisable		Exercise Price
$	0.14	-	$	0.15		487,750	$	0.14		4.5		487,750	$	0.14
$	3.05	-	$	3.05		182,100		3.05		3.4		182,100		3.05
$	3.13	-	$	3.13		50,000		3.13		1.4		50,000		3.13
$	3.86	-	$	4.10		72,000		3.97		1.4		72,000		3.97
$	5.29	-	$	6.93		931,170		6.38		0.6		931,170		6.38
$	7.48	-	$	7.48		1,500		7.48		2.5		1,500		7.48
$	0.14	-	$	7.48		1,724,520	$	4.07		2.5		1,724,520	$	4.07

(b) Warrants. As of June 30, 2013, the Company had 500,000 warrants outstanding to purchase shares of common stock at $0.80. These warrants expired unexercised in October 2013.